Kymera Therapeutics

Pathway Program Indication(s) Discovery Pre-Clinical Clinical Next
Milestone
Rights*

IL–1R/
TLR
IRAK4 HS (Focus), AD, RA, Others KT-474
Next Generation
IRAKIMiD
(IRAK4, Ikaros, Aiolos)
MYD88
MT
DLBCL
JAK/
STAT
STAT3 Liquid,
Solid Tumors
STAT3 Autoimmune, Fibrotic Diseases

Pegasus Platform Internal Leveraging the capabilities of our Pegasus platform, we are advancing multiple degrader programs in immunology-inflammation and genetically defined oncology indications
Partnered Our strategic collaboration with Sanofi includes a degrader program targeting IRAK4 and a second earlier stage program
Our strategic collaboration with Vertex is focused on the research and development of degraders against at least 6 targets in disease areas outside of our core strategic focus of immunology-inflammation and oncology

Oncology Immunology-Inflammation *Kymera retains the option to participate in U.S. development and commercialization for Sanofi-partnered programs.
Pathway
IL-1R/TLR
Program Indication(s) Rights*

IRAK4 HS (Focus), AD, RA, Others
Discovery Pre-Clinical Clinical Next
Milestone

KT-474
Next Generation
IRAKIMiD (IRAK4, Ikaros, Aiolos) MYD-88 MT    DLBCL
Discovery Pre-Clinical Clinical Next
Milestone

Pathway
JAK/STAT
Program Indication(s) Rights*

STAT3 Liquid,Solid Tumors
Discovery Pre-Clinical Clinical Next
Milestone

STAT3 Autoimmune, Fibrotic Diseases
Discovery Pre-Clinical Clinical Next
Milestone


Pathway
Pegasus Platform
Program Indication(s) Rights*

Internal Leveraging the capabilities of our Pegasus platform, we are advancing multiple degrader programs in immunology-inflammation and genetically defined oncology indications
Partnered Our strategic collaboration with Sanofi includes a degrader program targeting IRAK4 and a second earlier stage program
Our strategic collaboration with Vertex is focused on the research and development of degraders against at least 6 targets in disease areas outside of our core strategic focus of immunology-inflammation and oncology

Oncology Immunology-Inflammation
*Kymera retains the option to participate in U.S. development and commercialization for Sanofi-partnered programs.